Pan-antiviral peptides and uses thereof
Methods for preparing viral neuraminidase inhibitors including antiviral peptides by specifically chemically modifying disulfide bonds in precursor molecules. A method of inhibiting viral neuraminidases by administrating a viral neuraminidase inhibitor comprising an antiviral peptide prepared by the above methods and inhibiting the viral neuraminidase. Therapeutics for inhibiting viral neuraminidases, including effective amounts of viral neuraminidase inhibitors including antiviral peptides derived from selectively chemically modified disulfide bonds in precursor molecules, and present in a pharmaceutically acceptable carriers.
1. A method for inhibiting a viral neuraminidase, comprising contacting a viral neuraminidase with a peptide selected from the group consisting of:
a) a peptide prepared using a method comprising specifically chemically modifying disulfide bonds in an α-neurotoxin, wherein said specifically chemically modifying step comprises:
i) specifically reducing the disulfide bond with a reducing agent to form sulfhydryl groups; and,
ii) subsequently adding a blocking reactant that forms covalent bonds with the reduced sulfhydryl groups to prevent reoxidation of the sulfhydryl groups; wherein the reduced and blocked peptide has antiviral activity; and,
b) a peptide comprising the following characteristics:
i) the peptide comprises the amino acid sequence of a native α-neurotoxin;
ii) the cysteines normally involved in forming disulfide bonds are oxidized so they are unable to form disulfide bonds, such that the peptide lacks disulfide bonds;
iii) the amino acids of the peptide are unmodified, except for lacking disulfide bonds; and,
iv) the peptide has antiviral activity.
2. The method of claim 1 , wherein the α-neurotoxin is a Type I α-neurotoxin or Type II α-neurotoxin.
3. The method of claim 1 , wherein the α-neurotoxin is from a snake selected from the group consisting of cobra, rattlesnake and banded krait.
4. A method for inhibiting replication of a virus, comprising contacting the virus with a peptide selected from the group consisting of:
a) a peptide prepared using a method comprising specifically chemically modifying disulfide bonds in an α-neurotoxin, wherein said specifically chemically modifying step comprises:
i) specifically reducing the disulfide bond with a reducing agent; and,
ii) subsequently adding a blocking reactant that forms covalent bonds with the reduced sulfhydryl groups to prevent reoxidation of the sulfhydryl groups; wherein the reduced and blocked peptide has antiviral activity; and,
b) a peptide comprising the following characteristics:
i) the peptide comprises the amino acid sequence of a native α-neurotoxin;
ii) the cysteines normally involved in forming disulfide bonds are oxidized so they are unable to form disulfide bonds, such that the peptide lacks disulfide bonds;
iii) the amino acids of the peptide are unmodified, except for lacking disulfide bonds; and,
iv) the peptide has antiviral activity.
5. The method of claim 4 , wherein the α-neurotoxin is a Type I α-neurotoxin or a Type II α-neurotoxin.
6. The method of claim 4 , wherein the α-neurotoxin is from a snake selected from the group consisting of cobra, rattlesnake and banded krait.
7. The method of claim 4 , wherein the virus belongs to a family selected from the group consisting of Orthomyxoviridae and Paramyxoviridae.
8. The method of claim 4 , wherein the virus is selected from the group consisting of Semliki Forest Virus, Influenza A virus, Influenza B virus, Influenza C virus, Mumps virus, Sendai virus, Newcastle Disease virus, Canine distemper virus, adenovirus type 2, coronavirus, Parainfluenza virus, Canine parvovirus, Feline parvovirus, herpesvirus, Feline calicivirus, Feline leukemia virus, and Feline immunodeficiency virus.
9. A method for treating a patient having a viral infection, comprising administering to the patient a peptide selected from the group consisting of:
a) a peptide prepared using a method comprising specifically chemically modifying disulfide bonds in an α-neurotoxin, wherein said specifically chemically modifying step comprises:
i) specifically reducing the disulfide bond with a reducing agent; and,
ii) subsequently adding a blocking reactant that forms covalent bonds with the reduced sulfhydryl groups to prevent reoxidation of the sulfhydryl groups; wherein the reduced and blocked peptide has antiviral activity; and,
b) a peptide comprising the following characteristics:
i) the peptide comprises the amino acid sequence of a native α-neurotoxin;
ii) the cysteines normally involved in forming disulfide bonds are oxidized so they are unable to form disulfide bonds, such that the peptide lacks disulfide bonds;
iii) the amino acids of the peptide are unmodified, except for lacking disulfide bonds; and,
iv) the peptide has antiviral activity.
10. The method of claim 9 , wherein the α-neurotoxin is a Type I α-neurotoxin or a Type II α-neurotoxin.
11. The method of claim 9 , wherein the α-neurotoxin is from a snake selected from the group consisting of cobra, rattlesnake and banded krait.
12. The method of claim 9 , wherein the viral infection is due to at least one virus from a family selected from the group consisting of Orthomyxoviridae and Paramyxoviridae.
13. The method of claim 9 , wherein the viral infection is due to at least one virus selected from the group consisting of Semliki Forest Virus, Influenza A virus, Influenza B virus, Influenza C virus, Mumps virus, Sendai virus, Newcastle Disease virus, Canine distemper virus, adenovirus type 2, coronavirus, Parainfluenza virus, Canine parvovirus, Feline parvovirus, herpesvirus, Feline calicivirus, Feline leukemia virus, and Feline immunodeficiency virus.
14. A method for treating an individual having a cancer selected from the group consisting of malignant melanoma, leukemia and lymphoma, comprising administering to the individual a peptide selected from the group consisting of:
a) a peptide prepared using a method comprising specifically chemically modifying disulfide bonds in a precursor molecule, wherein said specifically chemically modifying step comprises:
i) specifically reducing the disulfide bond with a reducing agent; and,
ii) subsequently adding a blocking reactant that forms covalent bonds with the reduced sulfhydryl groups to prevent reoxidation of the sulfhydryl groups; wherein the reduced and blocked peptide has antiviral activity; and,
b) a peptide comprising the following characteristics:
i) the peptide comprises the amino acid sequence of a native α-neurotoxin;
ii) the cysteines normally involved in forming disulfide bonds are oxidized so they are unable to form disulfide bonds, such that the peptide lacks disulfide bonds;
iii) the amino acids of the peptide are unmodified, except for lacking disulfide bonds; and,
iv) the peptide has antiviral activity.
15. The method of claim 14 , wherein the α-neurotoxin is a Type I α-neurotoxin a Type II α-neurotoxin.
16. The method of claim 14 , wherein the α-neurotoxin is from a snake selected from the group consisting of cobra, rattlesnake and banded krait.
17. The method of claim 14 , wherein the cancer is malignant melanoma.